Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Statistical Considerations in the Intent-to-Treat Principle

Lachin, John M. · 2000 · Controlled Clinical Trials

Abstract

This paper describes some of the statistical considerations in the intent-to-treat design and analysis of clinical trials. The pivotal property of a clinical trial is the assignment of treatments to patients at random. Randomization alone, however, is not sufficient to provide an unbiased comparison of therapies. An additional requirement is that the set of patients contributing to an analysis provides an unbiased assessment of treatment effects, or that any missing data are ignorable. A sufficient condition to provide an unbiased comparison is to obtain complete data on all randomized subjects. This can be achieved by an intent-to-treat design wherein all patients are followed until death or the end of the trial, or until the outcome event is reached in a time-to-event trial, irrespective of whether the patient is still receiving or complying with the assigned treatment. The properties of this strategy are contrasted with those of an efficacy subset analysis in which patients and observable patient data are excluded from the analysis on the basis of information obtained postrandomization. I describe the potential bias that can be introduced by such postrandomization exclusions and the pursuant effects on type I error probabilities. Especially in a large study, the inflation in type I error probability can be severe, 0.50 or higher, even when the null hypothesis is true. Standard statistical methods for the analysis of censored or incomplete observations all require the assumption of missing at random to some degree, and none of these methods adjust for the potential bias introduced by post hoc subset selection. Nor is such adjustment possible unless one posits a model that relates the missing observations to other observed information for each subject-models that are inherently untestable. Further, the subset selection bias is confounded with the subset-specific treatment effect, and the two components are not identifiable without additional untestable assumptions. Methods for sensitivity analysis to assess the impact of bias in the efficacy subset analysis are described. It is generally believed that the efficacy subset analysis has greater power than the intent-to-treat analysis. However, even when the efficacy subset analysis is assumed to be unbiased, or have a true type I error probability equal to the desired level alpha, situations are described where the intent-to-treat analysis in fact has greater power than the efficacy subset analysis. The intent-to-treat design, wherein all possible patients continue to be followed, is especially powerful when an effective treatment arrests progression of disease during its administration. Thus, a patient benefits long after the patient becomes noncompliant or the treatment is terminated. In such cases, a landmark analysis using the observations from the last patient evaluation is likely to prove more powerful than life-table or longitudinal analyses. Examples are described.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0197-2456(00)00046-5

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 75 references

Research works printed but not linked: 4

  1. Tsiatis, 1990, Analysis and interpretation of trial results, J Acquir Immune Defic Syndr, 3, S120
  2. Food and Drug Administration. International Conference on Harmonization: Guidance on general considerations for clinical trials. Federal Register 1997; 62(242):66113–66119.
  3. Food and Drug Administration. International Conference on Harmonization: Guidance on statistical principles for clinical trials. Federal Register 1998; 63(179):49583–49598.
  4. Heyting, 1993, Author's Reply, Stat Med, 12, 2248

Cited by

See all 652

Metadata

Authors
Lachin, J. M.
Affiliations
George Washington University (US)
Corresponding author
Lachin, John M.
Venue
Controlled Clinical Trials
Publisher
Elsevier BV
Published
2000-06
Volume
21
Issue
3
Pages
167-189
ISSN
0197-2456 (ISSN-L)
OpenAlex
W1996932065
Cited by
652
References
75
Citations by year
2026: 11 · 2025: 18 · 2024: 19 · 2023: 16 · 2022: 21 · 2021: 21 · 2020: 24 · 2019: 25 · 2018: 22 · 2017: 29 · 2016: 19 · 2015: 38 · 2014: 44 · 2013: 34 · 2012: 43
FWCI
11.05
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Controlled Clinical Trials (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods and Bayesian Inference
  • Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
Keywords
intention-to-treat analysis, type I error inflation, missing at random, treatment effect estimation, statistical power, landmark analysis, time-to-event data, censored observations, sensitivity analysis, treatment non-adherence, randomization bias
MeSH terms
Clinical Trials as Topic, Data Interpretation, Statistical, Probability, Models, Statistical, Bias, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statistical Considerations in the Intent-to-Treat Principle. https://app.cochat.ai/papers/10.1016/s0197-2456(00)00046-5
The paper
Lachin, J. M. (2000). Statistical Considerations in the Intent-to-Treat Principle. Controlled Clinical Trials. https://doi.org/10.1016/s0197-2456(00)00046-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.